Ipsen Strengthens Early Clinical Pipeline With IRLAB’s Mesdepotem For Levodopa-Induced Dyskinesia

Upfront Of $28m

Parkinson's disease
• Source: Alamy

More from Neurological

More from Therapeutic Category